Introduction
============

Around the world, cervical cancer (CC) is the fourth most common cancer among women, accounting for an estimated 529,572 diagnosed new cases and 274,967 deaths per year **[@B1]**. This cancer is the 3rd-leading cause of death in women\' neoplasis worldwide and the morbidity of cervical cancer has increased recently **[@B2]**. In China, the cervical cancer has become the first major female cancer (98.9 per 100000) in addition to breast cancer. The mortality rate is up to 30.5 per 100000. And the incidence rate has the increasing trends **[@B3]**.

Although several factors that contribute to cervical cancer development have been identified---mainly intrinsic factors (genetic), and extrinsic factors belonging to the high risk Human Papillomavirus (HR-HPV)---genetic factors show great potential as susceptibility or prognosis indicators**[@B4],[@B5]**. Only a small fraction (\~1%) of cervical HR-HPV infection outcomes to cervical neoplasia, and the factors determining risk of progression are not entirely understood **[@B6]**. Many genetic variants were associated with the risk of cervical cancer as supported by the epidemiological evidence **[@B7]**.

Genomic instability due to DNA damage by carcinogens has been implicated in the initiation and development of cancer. DNA damage response and repair counteract the threats to genomic integrity, and variations in DNA repair capacity resulting from genetic variants could correlate with cancer predisposition **[@B8]-[@B11]**. The base excision repair (BER) pathway is the major DNA genetic damage repair pathway involved in genomic instability and tumorigenesis. Previous candidate gene studies showed that selected functional single nucleotide polymorphisms (SNP) in BER genes are associated with higher risk of several solid cancers **[@B12]-[@B17]**.

Single-strand selective mono-functional uracil-DNA glycosylase (SMUG1) is one of the BER genes which remove uracil from double-stranded and single-stranded DNA to maintain genomic stability following oxidative attacks **[@B18]**. SNPs in this gene could have an effect on its enzyme capability of repairing DNA damage.

Xie et al evaluated the associations of 167 SNPs from 19 genes of the BER pathway with the risk of bladder cancer. 13 SNPs in 10 BER pathway genes were significantly associated with bladder cancer risk. The most significant SNP was rs2029167 in the SMUG1 gene **[@B19]**. Similar studies also found a correlation between SNP of SMUG1 with breast cancer **[@B20]** and colorectal cancer (CRC) **[@B21]**. Until now, there is no report of SNP of SMUG1 in cervical cancer.

In this large scale case-control study, the aim was to investigate the relationship between the four intron SNPs (rs3087404, rs2029167, rs2029166 and rs7296239) of SMUG1 and the susceptibility of cervical squamous cell carcinoma (CSCC). Genotyping analyses of the four SMUG1 SNPs were performed in 400 CSCCs, 400 precursor lesion CIN III and 1200 normal controls.

Materials and methods
=====================

Study samples selection
-----------------------

400 CSCC cases, 400 CIN III cases and 1200 normal controls were recruited from Zhejiang Province, China. The diagnosis was determined by two pathologists. All subjects were unrelated ethnic Chinese women and recruited between 2004 Jun to 2008 Dec. Normal controls were randomly selected from healthy women volunteers during gynecologic examinations. The inclusion criteria for healthy volunteers were without gynecological neoplasm, cytological findings, endometriosis, other solid cancer and immune disorders.

Patients with pathological diagnosis of CINIII and cervical squamous cell carcinoma (CSCC) were included in the study. Considering that patients with CINI and CINII have unstable disease progression, we excluded these patients and only selected patients with CINIII. All cases of CSCC were FIGO stage Ia-IIb, histologically confirmed primary cervical carcinoma, treated radical hysterectomy with pelvic lymph node dissection, and did not receive any anticancer therapy prior to their surgery. Patients who are eligible for any of the following criteria are excluded: over 70 years of age, with other serious complications, or previous malignant disease.

Of these, 201 CSCC patients, 357 CIN III patients and 609 normal controls agreed to provide cervical brush-off samples for detecting HR-HPV. This study was approved by the Medical Ethical Committee of Women\'s Hospital, School of Medicine, Zhejiang University (No.2004002). All patients signed informed consent.

DNA Extraction and Genotyping
-----------------------------

Genomic DNA was extracted from anticoagulant peripheral blood using a DNA extraction kit according to the manufactor\'s guideline (Sangon Bioengineering Co., Shanghai, China). All DNA samples were dissolved in water and hypothermic preservation ready to use.

The four intron SNPs (rs3087404\[A/G\], rs2029167 \[A/G\], rs2029166 \[C/T\] and rs7296239 \[C/T\]) of SMUG1was detected by Modified polymerase chain reaction-mismatch amplification (MA-PCR) (As described in detail previously **[@B22]**). The PCR forward and reverse primers and product length were showed in following table [1](#T1){ref-type="table"}.

The PCR was performed in a 25ul reaction mixture, containing 50 ng of genomic DNA, 5.0 pmol of each primer, 0.2 mM of each dNTP and 1.0U of Taq DNA polymerase (TAKARA, Dalian, China). PCR undertook the following conditions: an initial denaturation at 94°C for 5 min, followed by 35 cycles of 94°C for 30s, 57°C for 30s, and 72°C for 1min, and a final step of 72°C for 10min. The PCR products were developed by 1.5% agarose gel electrophoresis, stained with ethidium bromide and visualized with a TyphoonTM 9410 Imaging System (GE Healthcare, USA). All samples were tested twice in double blind by two different technicians, and the reproducibility of the experiment was 100%.

HR-HPV detection
----------------

HR-HPV infection was identified using the Hybrid Capture II(HC II) assay (Digene Diagnostics Inc., Gaitherburg, MD, USA) using probe B, which includes a pool of RNA probes for HR-HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Cervical sampling for HR-HPV DNA was performed with the Digene Cervical Sampler.

SMUG1 mRNA expression by qRT-PCR
--------------------------------

Freshly frozen tumor tissues of eighty seven CSCCs were selected. Total RNA was extracted using Trizol reagent according to the manufacturer\'s protocol (Invitrogen, USA). Total RNA was treated with RNase-free DNase I. cDNA was reversed transcription and used as a template for qPCR detection. The following PCR primer pairs were used for quantitative amplification; 95°C 30s, 40 cycles at 95°C 5s followed with 60°C 30s. The primers of SMUG1 (mRNA: NM_001243787.1) were 5\'-CGCAACTACGTGACTCGCTA-3\'; 5\'-GTCCCAGCACTGGTCGTTTA- 3\'. GAPDH was used as internal control. The primers of GAPDH (mRNA: NM_001256799.2) were 5\'-GAGAAGGCTGGGGCTCATTT-3\'; 5\'-AGTGATGGCATGGACTGTGG-3\'. The PCR product length of SMUG1 and GAPDH were 190bp and 231 bp, respectively. All reactions were performed with a ViiA 7 Dx System (ABI). The cutoff point (Ct) was defined as the value when the fluorescent signal increased above the background threshold. The ΔCt for gene-specific mRNA expression was calculated relative to the Ct of GAPDH. Relative mRNA expression was calculated with the formula: 2^-ΔCt^.

SMUG1 protein expression by Western blotting
--------------------------------------------

Eighty seven freshly CSCCs tissues were used to detect SMUG1 protein expression. Briefly, the tissue samples were minced on ice, and then the tissue was homogenized in the RIPA protein lysis buffer. The homogenized mixtures were rotated in the tubes at 4℃ for 1 h, and after centrifugation at 12,000 rpm at 4℃, the supernatant was collected and the protein concentrations were quantified.

10μl protein lysates were loaded into an 8% PAGE gel. Subsequently, electrophoretic separated proteins were transferred onto a 0.45µm PVDF membrane. After blocking with 5% non-fat milk for 1h, PVDF membrane was incubated with primary mouse monoclonal antibodies: SMUG1 (1:2000) purchased from NOVUS Biologicals (Cat No. H00023583-M07) and GAPDH (1:5000) purchased from Proteintech(Cat No. Cat.60004-1-Ig) for 4°C overnight, then were washed with TBS containing 0.05%Tween-20 for three times, followed by a 1h incubation with an HRP-conjugated secondary antibody (1:5000). After washing with TBS, the membranes were imaged with ECL using an Image Quant LAS 4000 mini (GE Healthcare).

Statistical Analysis
--------------------

For the association between the genotypes and risk of cervical carcinoma, the odds ratio (OR), 95% confidence intervals (CIs) and *P*-values were obtained by binary logistic regression analysis. The control was set as the reference group for analysis. Stratified analysis of life style habits and genotype frequencies were evaluated with Kruskal-Wallis H test. The differences of quantitative mRNA and protein expression were calculated by ANOVA with a post hoc analysis (Fisher least significant difference). All reported values are two-tailed. The level of statistically significant difference was set at P≤0.05. All statistical analysis was done with SPSS software 18.0 ver for Windows.

Results
=======

Clinical Features of Cases and Controls
---------------------------------------

40 years old/40 years old individuals were 602/598, 258/ 142 and 160/240 in the control, CIN III and carcinoma respectively. The carcinoma group had significantly more individuals \>40 years old, but the CIN III group had more \<40 years old individuals (P\<0.001) compared to the control. There was no significant difference beside the increase of the proportion of individuals with number of parities more than 3 in the CIN III and carcinoma groups. The HR- HPV infection rate was 31.4%, 86.8% and 88.6% in the control, the CIN III and the carcinoma, respectively. HR-HPV infection in CIN III and cervical carcinoma cases were more than in controls. The Table [2](#T2){ref-type="table"} and data are quoted from our previously published work **[@B23]**.

Correlation analysis of SMUG1 SNPs Genotypes with risk of CSCC
--------------------------------------------------------------

Table [3](#T3){ref-type="table"} represents the genotypic and allelic frequencies of SMUG1 rs3087404, rs2029166, rs2029167 and rs7296239. Genotype distributions were in Hardy-Weinberg equilibrium. The CC, CT, and TT frequency of SMUG1 rs2029166 was 42.1%, 46.1% and 11.6% in the controls, 40.8%, 45.3% and 14.0% in the CIN III, 43.5%, 39.8% and 16.8% in CSCCs. The TT, TC, and CC frequency of SMUG1 rs7296239 was 33.0%, 51.9% and 15.1% in the controls, 36.0%, 51.8% and 12.3% in the CIN III, 34.8%, 49.3% and 16.0% in CSCCs, respectively. These results indicated that the SMUG1 rs2029166 and rs7296239 polymorphism were not associated with the risk for CIN III or CSCCs.

The AA, AG, and GG frequency of SMUG1 rs3087404 was 34.5%, 54.9% and 10.6% in the controls, 35.3%, 45.5% and 19.3% in the CIN III, 28.3%, 36.8% and 35.0% in CSCCs, respectively. These results revealed that women with the homozygous GG of rs3087404 had a significantly increased risk of CIN III \[OR=1.78(1.27-2.51), P= 0.001\] and CSCC \[OR=4.04 (2.94-5.55), P=0.000\]. We observed "A" allele is the major form at rs3087404 in controls (62.0%, 1487/ 2400), but "G" allele is the major form in CSCCs (53.4%, 427/800). The increased risk of "G" allele in CIN III and CSCCs were 1.78(1.00-1.39) and 1.86 (1.59-2.19) respectively. Data also indicated that individuals with "G" allele or "G" carrier (AG +GG) at rs3087404 were at higher risk for CSCCs \[OR=1.34 (1.04-1.71), P= 0.022\].

The AA, AG, and GG frequency of SMUG1 rs2029167 was 37.9%, 44.3% and 17.8% in the controls, 30.3%, 33.5% and 36.3% in the CIN III, 24.3%, 29.8% and 46.0% in CSCCs, respectively. These results revealed that women with the homozygous GG of rs2029167 had an increased risk of CIN III \[OR=2.56 (1.91-3.43), P= 0.000\] and CSCCs \[OR=4.05(3.02-5.44), P=0.000\]. "A" allele is the major form at rs2029167 in controls (60.1%, 1442/2400), but "G" allele is the major form in CIN III (53.0%, 424/800) and in CSCCs (60.9%, 487/800). "G" allele at rs2029167 was significantly higher in CIN III and CSCCs compared with normal controls. The increased risk of "G" allele in CIN III and CSCCs were OR=1.70(1.45-1.99) and OR=2.34(1.99-2.76) respectively. "G" allele or "G" carrier (AG +GG) at rs2029167 were at higher risk for CINIII \[OR=1.41(1.10-1.80), P= 0.006\] and CSCCs \[OR=1.91 (1.48-2.47), P= 0.000\].

As show in Table [4](#T4){ref-type="table"}, in the HR-HPV positive group, though the homozygous GG of rs3087404 have not increased the risk of CIN III \[OR=1.43(0.80-2.53, P= 0.226\], it significantly increased the risk of CSCCs \[OR=3.91(2.15-7.15), P=0.000\], the increased risk of "G" allele in CSCCs were OR=1.94(1.45-2.60). The homozygous GG of rs2029167 had an increased risk of CIN III \[OR=2.40 (1.48-3.89), P= 0.000\] and CSCCs \[OR=3.88(2.26-6.88), P=0.000\]. Meanwhile, the increased risk of "G" allele in CIN III and CSCCs were OR=1.66(1.29-2.15) and OR=2.35(1.75-3.15).

Association between SMUG1 rs3087404, rs2029167 polymorphisms and the Sexual, Reproductive History in CSCCs and CIN III
----------------------------------------------------------------------------------------------------------------------

As show in Table [5](#T5){ref-type="table"}, the participants were divided into two groups according to Age, age of first sexual intercourse, number of sexual partners, age at first parity, number of parities and HR-HPV infection, then stratified analysis was done with the SMUG1 rs3087404 (A/G) and rs2029167 (A/G) genotype. Stratified analysis of age, number of parities, and age at first parity showed no correlation with rs3087404 (A/G) polymorphisms. However, we find a particularly high level of enrichment between groups with stratified analysis of the number of sexual partners in the CIN III (χ^2^=15.610, P=0.000) and CSCCs (χ^2^=13.468, P=0.000), and the age of first sexual intercourse in the CIN III (χ^2^=18.453, P=0.000) and CSCCs (χ^2^=15.528, P=0.000). We also did not find a high level of enrichment between HR-HPV positive and negative group of CIN III (χ^2^=0.176, P=0.675) and CSCCs (χ^2^=0.017, P=0.895).

Data display of rs2029167 (A/G) as show in Table [6](#T6){ref-type="table"}, we did not find a particularly high level of enrichment between groups, except for the number of sexual partners in the CIN III (χ^2^=10.214, P=0.001) and CSCCs (χ^2^=12.366, P=0.000), there was a particularly high level of enrichment.

Association between SMUG1 rs3087404, rs2029167 polymorphisms and the Clinical pathological characteristics in CSCCs
-------------------------------------------------------------------------------------------------------------------

The correlation of SMUG1 rs3087404 and rs2029167 polymorphisms with CSCCs clinicopathological characteristics is shown in Table [7](#T7){ref-type="table"}.The CSCCs were divided into two groups according to age, tumor family history, FIGO stage, tumor size, differentiation grade, lymph node metastasis, vascular involvement, stromal invasion, vaginal wall extension, parametrial extension, and endometrial extension, then stratified analysis was done with the SMUG1 rs3087404 (A/G) and rs2029167 (A/G) genotype.

Stratified analysis of age, FIGO stage, tumor size, lymph node metastasis, vascular involvement, stromal invasion, vaginal wall extension, parametrail extension, and endometrial extension showed no correlation with rs3087404 (A/G) or rs2029167 (A/G) polymorphism. However, we found a particularly high level of enrichment of rs3087404 (χ^2^=9.265, P= 0.002)) and rs2029167 (χ^2^=8.112, P=0.004) when stratified by differentiation grade. This means that GG homozygotes of rs3087404 and rs2029167 are significantly associated with the degree of malignancy of tumor differentiation. In addition, interestingly, we found that GG homozygote of rs3087404 is also associated with a family history of the tumor (χ^2^=8.792, P=0.003).

mRNA and protein expression from patients with different genotypes of SMUG1 rs3087404 (A/G) or rs2029167 (A/G)
--------------------------------------------------------------------------------------------------------------

As shown in **Figure [1](#F1){ref-type="fig"}**, among the 87 CSCCs patients, the genotypes of AA, AG, and GG at rs3087404 were 25(28.7%), 32(36.8%) and 30(34.5%) cases, while the genotypes of AA, AG, and GG at rs2029167 were 22(25.3%), 26(30.0%) and 39(44.8%) cases, respectively. There was no significant difference in the expression of SMUG1 mRNA with different genotypes at rs3087404 (F=1.022, P=0.364) or at rs2029167 (F=2.067, P=0.133).

As shown in **Figure [2](#F2){ref-type="fig"}**, Western Blot experiments confirmed that the polymorphism of rs3087404 did not affect the expression of SMUG1 protein (F=0.254, P=0.781). Similarly, the polymorphisms of rs2029167 is also independent of the expression level of SMUG1 protein (F=1.346, P=0.308).

Haplotype Analysis between the Linkage Disequilibrium of the SMUG1 rs3087404 and rs2029167 Variants Genotypes and the Risk of CIN III and CSCCs
-----------------------------------------------------------------------------------------------------------------------------------------------

Since that the frequencies of both rs3087404 (A/G) and rs2029167 (A/G) genotypes change the risk of CIN III or CSCCs significantly, we further analyzed the linkage disequilibrium between rs3087404 (A/G) and rs2029167 (A/G). The frequencies of the nine haplotypes were shown in Table [8](#T8){ref-type="table"}. GG (rs3087404)-GG (rs2029167) was not detected in normal control and CSCCs, except for 1 case detected in CIN III. Compared to AA (rs3087404)-AA (rs2029167), the genotype with AA-GG \[OR=3.14 (1.95-5.05), P=0.000\], AG-GG \[OR=2.45(1.58-3.89), P= 0.000\], GG-AA \[OR=2.24(1.28-3.90), P=0.005\], GG-AG \[OR=2.58(1.54-4.32), P=0.027\] significantly increased the risk of CIN III. More notably, this risk is much greater in CSCC: AA-GG \[OR=7.13(4.03-12.61), P= 0.000\], AG-GG \[OR=7.22(4.21-12.38), P=0.000\], GG- AA \[OR=8.60(4.73-15.63), P=0.000\], GG-AG \[OR=9.64 (5.43-17.13, P=0.000\]. This means that whether the rs3087404 or rs2029167 is GG homozygote, the linkage mode is at high risk. We also found that women with the AG-AG genotype had a decreased risk for CSCCs \[OR=0.49(0.25-0.96), P=0.038\].

Additionally, most GG (rs3087404) genotypes were linkage GG-AG (44/77, 80/140) in the CIN III and CSCC, while most GG (rs2029167) genotypes were linkage genotype AG-GG (79/145, 112/184) in the CIN III and CSCCs, respectively. These indicated that the majority of GG genotype distributions are caused by the linkage disequilibrium with the corresponding alleles.

Discussion
==========

Uracil misincorporation into DNA arises spontaneously at low level as a result of cytosine deamination or misincorporation of dUMP during DNA replication **[@B24], [@B25]**. Under normal conditions, such lesions are rapidly recovered by the BER pathway initiated by uracil-DNA glycosylases (UDG) **[@B26], [@B27]**. In most organisms, including humans, uracil is generally an undesirable ingredient in the genome. Thus strategies are in place to remove uracil once occurring of the DNA damage. So, sophisticated mechanisms are essential for the removal of uracil from DNA and prevention of its misincorporation, and maintain genomic integrity and stability. The failure of removing misincorporated uracil from DNA will result in base abnormity during DNA replication, even lead to dsDNA breaks and chromosomal aberrations, these two events are the key genetic factors of tumorigenesis**[@B25], [@B28]-[@B30]**.

BER is a highly conserved DNA repair system from bacteria to humans **[@B31]-[@B33]**. A great variety of DNA-damaging agents can cause genome instability, which would be a tremendous matter for cells if the damaged DNA is not recovered **[@B11]**. The most important role of BER is to remove DNA damage caused by various carcinogens, such as reactive oxygen species (ROS), ionizing radiation and so on**[@B34]**. In humans, four UDGs have been identified, encoded by the UNG, SMUG1, MBD4 and TDG genes **[@B33],[@B35],[@B36]**. Most of these critical BER genes are highly polymorphic **[@B37]**. Genetic variations of these genes are likely to alter BER enzyme functional activity, and influence cancer risk **[@B36]**.

The human single-strand-selective monofunctional uracil-DNA glycosylase 1(SMUG1; also named: FDG, UNG3 and HMUDG) is located in the Chromosome 12q13.11-13.3 **[@B26], [@B38]**. This gene encodes for a uracil DNA glycosylase (UDG) of the BER pathway that removes uracil, from single stranded (ssDNA) as well as double stranded DNA (dsDNA) **[@B39]**. As SMUG1 removes uracil and 5-hmeU from ssDNA and dsDNA, this enzyme may take participate in the repair of deamination and oxidation damage. The SMUG1 is the major enzyme involved in the removal of 5-hmeU from damaged DNA **[@B40]**.

Several researchers reported the SNPs of SMUG1were correlationship with bladder cancer, breast cancer and CRC susceptibility. In a matched study of 801 bladder cancer cases, Xie et al. found 13 SNPs in10 BER pathway genes significantly increased the risk of bladder cancer. The most significant variant was SMUG1 rs2029167 (A/G). The homozygous GG genotype increased a 1.42-fold risk of bladder cancer **[@B19]**.In another 1,077 case-controls matched study of incident breast cancer, Marian et al suggested that there was increased risk of breast cancer among postmenopausal women who were heterozygous of two of SMUG1 SNPs which is thought to be the most active glycosylase *in vivo*, raises the possibility that subtle \'heterosis\' effects on cancer risk might be produced by these SNPs **[@B20]**. In a study of CRC, Broderick et al reported that genetic variations in TDG, UNG and SMUG1 may play a role in the susceptibility of CRC **[@B21]**. These reports remind us to make a hypothesis which there is an association between the genetic variants of SMUG1 gene with cancer risk. We carried out the correlation study of cervical cancer and SMUG1 SNPs.

The initiation and development of cervical carcinoma involves reversible transformation in the cervical squamous cells resulting in various cellular abnormalities and ultimately to cervical tumorigenesis. The development of cervical carcinoma usually requires multiple stages, eventually developing from precursor lesion cervical intraepithelial neoplasia (CIN) to cervical malignant carcinoma **[@B21].** In our results, the two of SMUG1 rs2029166 and rs7296239 polymorphisms were not associated with the risk for CIN III or CSCC. Interestingly, the homozygous GG of rs3087404 and rs2029167 had a significantly increased risk of CIN III and CSCC. We also observed the increased risk of G allele of these two SNP in CIN III and CSCC. The individuals with G allele or G carrier (AG +GG) at rs3087404 and rs2029167 were at higher risk for CSCC. These findings indicated that the SMUG1 rs2029166 and rs7296239 polymorphisms (G allele) maybe play a role in initiation and progression of precancerous lesions (CIN) and cervical carcinoma. So far, there is no study about the correlation between cervical carcinoma and the SMUG1 rs2029166 and rs7296239 polymorphisms (G allele). The present study is the first time to discover the association between the SMUG1 rs2029166 and rs7296239 polymorphisms (G allele) and cervical carcinoma or CIN III. In general, SNP loci that affect the structure and function of genes are located in the 5\' UTR promoter, coding region, or 3\' UTR region. Although our two variants both are located in the intron which cannot change the amino acid, it is possible that there is linkage disequilibrium with other functional genetic variants and serves as a genetic marker of susceptibility **[@B41]**. Another possibility is that the SMUG1 rs2029166 and rs7296239 genetic variants maybe influence primary mRNA splicing and regulation, and affects SMUG1 protein expression or produce alternative spliceosome. To validate the SMUG1 expression change, we detected the mRNA and protein expression in fresh tumor tissues in the different genotype groups of SMUG1 rs2029166 and rs7296239, but we discovered that there was no association between the genotype of SMUG1 rs2029166 and rs7296239 with SMUG1 gene mRNA or protein expression. These indicate that the tumor susceptibility induced by the polymorphism of this locus was not achieved by altering gene expression. Bonnet et al. speculated that the introns take participate in maintaining genetic stability at certain locations, particularly in highly expressed genes **[@B42]**, and repair genes are often high expression genes.

During the linkage disequilibrium analysis between rs3087404 (A/G) and rs2029167 (A/G), we found that whether the rs3087404 or rs2029167 is GG homozygote, the linkage mode is at high risk. Additionally, most GG (rs3087404) genotypes were linkage GG-AG (44/77, 80/140) in the CIN III and CSCCs, while most GG (rs2029167) genotypes were linkage genotype AG-GG (79/145, 112/184) in the CIN III and CSCCs, respectively. These indicated that the majority of GG genotype distributions are caused by the linkage disequilibrium with the corresponding alleles. These linkage modes can be used as genetic biomarker of early prediction of cervical carcinoma, as an indicator of primary prevention.

Stratified analysis of the number of sexual partners and the age of first sexual intercourse found that the rs3087404 (A/G) had a particularly high level of enrichment in the CIN III and CSCCs. About the rs2029167 (A/G), we only found a particularly high level of enrichment grouping by the number of sexual partners in the CIN III. This suggests that there may be a certain correlation between SMUG1 rs3087404 (A/G) and rs2029167 (A/G) variants with the female sexual behavior.

Among all of clinical parameters, we found that the genetic polymorphisms of rs3087404 (A/G) and rs2029167 (A/G) are significantly associated with the degree of malignancy of tumor differentiation; homozygous GG genotype increases the risk of malignant cell differentiation grade of tumors. In addition, interestingly, we found that GG homozygote of rs3087404 is also associated with a family history of the tumor. These indicate that there maybe a correlation between the SNPs of SMUG1 rs3087404 (A/G) and rs2029167 (A/G) with tumor cell differentiation and family heredity.

In HR-HPV positive group, we found that the homozygous GG of rs3087404 and rs2029167 both significantly increased the risk of CSCCs, only "G" allele or "G" carrier (AG +GG) at rs2029167 were at higher risk for CSCCs. But, in stratified analysis, we did not find a high level of enrichment between HR-HPV positive and negative groups of CIN III and CSCCs. These indicated that the rs3087404 and rs2029167 involved in the cervical tumorigenesis, but they maybe not affect the HR-HPVs infection at early onset of disease. In the process of affecting cervical tumorigenesis, rs2029167 variant may be more effective than those of rs3087404 variant.

These findings suggested that there was association between the two of SMUG1 rs3087404 (A/G) and rs2029167(A/G) genetic variant with the susceptibility of CIN III and CSCCs, but not HR-HPVs infection. Whether the rs3087404 or rs2029167 is GG homozygote, there was linkage disequilibrium between these two of polymorphism leading to increase the risk of CIN III and CSCC. These linkage modes can be used as genetic biomarker of early prediction of cervical carcinoma, as an indicator of primary prevention.
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###### 

The PCR forward and reverse primers

  SNP No.                 Forward primer                 Reverse primer                 Product length                 
  ----------------------- ------------------------------ ------------------------------ ------------------------------ -------
  rs3087404 **\[A/G\]**   For "**A**"                    5\'-CTCATCAAGAGACTGCTGGA-3\'   5\'-ACTTTCATTGTTCCATAACT-3\'   240bp
  For "**G**"             5\'-CTCATCAAGAGACTGCTGGG-3\'                                                                 
  rs2029167 **\[A/G\]**   For "**A**"                    5\'-GGGTGGTCCTCAGCTTGGCA-3\'   5\'-GCAGTGACTGGCAGGAGGCG-3\'   184bp
  For "**G**"             5\'-GGGTGGTCCTCAGCTTGGCG-3\'                                                                 
  rs2029166 **\[C/T\]**   For "**C**"                    5\'-GCCATCTCTCATGGATTAAC-3\'   5\'-TTATGAGATAGCAGTGACTG-3\'   228bp
  For "**T**"             5\'-GCCATCTCTCATGGATTAAT-3\'                                                                 
  rs7296239 **\[C/T\]**   For "**C**"                    5\'-CAGCCTCAACCCCAAAAGAC-3\'   5\'-TGGCTAATGTTGAGCGAAAT-3\'   128bp
  For "**T**"             5\'-CAGCCTCAACCCCAAAAGAT-3\'                                                                 

###### 

Frequency distribution of select features by case control status

  Variable                       Control      CIN III      *χ2\**      *P*           Carcinoma     *χ2^\*^*    *P*           
  ------------------------------ ------------ ------------ ----------- ------------- ------------- ----------- ------------- -------------
  Age                            ≤40          602 (50.2)   258(64.5)   **24.793**    **\<0.001**   160(40.0)   **12.431**    **\<0.001**
                                 \>40         598(49.8)    142(35.5)                               240(60.0)                 
  Age at the first intercourse   ≤20 years    359(29.9)    130(32.5)   0.943         0.331         125(31.3)   0.253         0.615
                                 \>20 years   841(70.1)    270(67.5)                               275(68.8)                 
  Number of sexual partners      ≤ 1          963(80.3)    316(79.0)   0.292         0.589         309(77.3)   1.657         0.198
                                 \>1          237(19.8)    84(21.0)                                91(22.8)                  
  Age at the first birth         ≤22years     235(19.6)    91(22.8)    1.854         0.173         89(22.3)    1.321         0.25
                                 \>22 years   965(80.4)    309(77.3)                               311(77.8)                 
  Number of parities^\*\*^       ≤ 3          548(45.7)    158(39.5)   **4.627**     **0.031**     131(32.8)   **20.49**     **\<0.001**
                                 \>3          652(54.3)    242(60.5)                               269(67.3)                 
  Smoking status                 smoker       4(0.3)       2(0.5)      0.223         0.637         2(0.5)      0.223         0.637
                                 nonsmoker    1196(99.7)   398(99.5)                               398(99.5)                 
  HR-HPV infection               Positive     191(31.4)    310(86.8)   **277.107**   **\<0.001**   178(88.6)   **199.315**   **\<0.001**
                                 Negative     418(68.6)    47(13.2)                                23(11.4)                  
                                 total        609          357                                     201                       

Bold values show statistical data with significant difference.^\*^ Two-sided χ2 test. ^\*\*^ Parities including full-term pregnancy and abortion at or after 28 weeks

###### 

Association between SMUG1 polymorphisms and the risk of CIN III and cervical carcinoma

  SMUG1 Genotypes   All patients and controls                                                                                                                                                          
  ----------------- --------------------------- ---------- ------ ------ ------ --------------------- --------------------- ----------- ------ --------------------- --------------------- ----------- --
  **rs3087404**                                                                                                                                                                                        
                    AA                          414        34.5   141    35.3   1.00(ref)                                   113         28.3   1.00(ref)                                               
                    AG                          659        54.9   182    45.5   0.81(0.63-1.04)       0.103                 147         36.8   0.82(0.62-1.08)       0.149                             
                    GG                          127        10.6   77     19.3   **1.78(1.27-2.51)**   **0.001**             140         35.0   **4.04(2.94-5.55)**   **0.000**                         
                    AG+GG                       786        65.5   259    64.8   0.97(0.76-1.23)       0.785                 287         71.8   **1.34(1.04-1.71)**   **0.022**                         
                    Allelic frequency                                                                                                                                                                  
                                                Allele A   1487   62.0   464    58.0                  1.00(ref)                         373    46.6                  1.00(ref)                         
                                                Allele G   913    38.0   336    42.0                  **1.78(1.00-1.39)**   **0.047**   427    53.4                  **1.86(1.59-2.19)**   **0.000**   
  **rs2029166**                                                                                                                                                                                        
                    CC                          504        42.0   163    40.8   1.00(ref)                                   174         43.5   1.00(ref)                                               
                    CT                          557        46.4   181    45.3   1.01(0.79-1.28)       0.969                 159         39.8   0.83(0.65-1.06)       0.131                             
                    TT                          139        11.6   56     14.0   1.25(0.87-1.78)       0.228                 67          16.8   1.40(1.00-1.96)       0.053                             
                    CT+TT                       696        58.0   237    59.3   1.05(0.84-1.33)       0.661                 226         56.5   0.94(0.75-1.18)       0.599                             
                    Allelic frequency                                                                                                                                                                  
                                                Allele C   1565   65.2   507    63.4                  1.00(ref)                         507    63.4                  1.00(ref)                         
                                                Allele T   835    34.8   293    36.6                  1.08(0.92-1.28)       0.347       293    36.6                  1.08(0.92-1.28)       0.347       
  **rs2029167**                                                                                                                                                                                        
                    AA                          455        37.9   121    30.3   1.00(ref)                                   97          24.3   1.00(ref)                                               
                    AG                          532        44.3   134    33.5   0.95(0.72-1.25)       0.700                 119         29.8   1.05(0.78-1.41)       0.750                             
                    GG                          213        17.8   145    36.3   **2.56(1.91-3.43)**   **0.000**             184         46.0   **4.05(3.02-5.44)**   **0.000**                         
                    AG+GG                       745        62.1   279    69.8   **1.41(1.10-1.80)**   **0.006**             303         75.8   **1.91(1.48-2.47)**   **0.000**                         
                    Allelic frequency                                                                                                                                                                  
                                                Allele A   1442   60.1   376    47.0                  1.00(ref)                         313    39.1                  1.00(ref)                         
                                                Allele G   958    39.9   424    53.0                  **1.70(1.45-1.99)**   **0.000**   487    60.9                  **2.34(1.99-2.76)**   **0.000**   
  **rs7296239**                                                                                                                                                                                        
                    TT                          396        33.0   144    36.0   1.00(ref)                                   139         34.8   1.00(ref)                                               
                    TC                          623        51.9   207    51.8   0.91(0.71-1.17)       0.474                 197         49.3   0.90(0.70-1.16)       0.415                             
                    CC                          181        15.1   49     12.3   0.74(0.52-1.08)       0.117                 64          16.0   1.00(0.71-1.42)       0.967                             
                    TC+CC                       804        67.0   256    64.0   0.88(0.69-1.11)       0.272                 261         65.3   0.93(0.73-1.17)       0.521                             
                    Allelic frequency                                                                                                                                                                  
                                                Allele T   1415   59.0   495    61.9                  1.00(ref)                         475    59.4                  1.00(ref)                         
                                                Allele C   985    41.0   305    38.1                  0.89(0.75-1.04)       0.145       325    40.6                  0.98(0.84-1.16)       0.836       

Bold values show statistical data with significant difference. \*All *P*-values are adjusted for age, number of sexual partners, age at first intercourse, parities (including full-term pregnancy and abortion at or after 28 weeks) and age at first full-term pregnancy.

###### 

Association between SMUG1 rs3087404 and rs2029167 polymorphisms with the risk of HR-HPV positive cervical carcinoma and CIN III

  SMUG1 Genotypes   HPV-positive patients and controls                                                                                                                                                          
  ----------------- ------------------------------------ ---------- ------ ------ ------ --------------------- --------------------- ----------- ------ --------------------- --------------------- ----------- --
  **rs3087404**                                                                                                                                                                                                 
                    AA                                   65         34.0   111    35.8   1.00(ref)                                   49          27.5   1.00(ref)                                               
                    AG                                   103        53.9   143    46.1   0.81(0.55-1.21)       0.307                 61          34.3   0.79(0.48-1.28)       0.332                             
                    GG                                   23         12.0   56     18.1   1.43(0.80-2.53)       0.226                 68          38.2   **3.91(2.15-7.15)**   **0.000**                         
                    AG+GG                                126        66.0   199    64.2   0.93(0.63-1.35)       0.686                 129         72.5   1.36(0.87-2.12)       0.177                             
                    Allelic frequency                                                                                                                                                                           
                                                         Allele A   233    61.0   365    58.9                  1.00(ref)                         159    44.7                  1.00(ref)                         
                                                         Allele G   149    39.0   255    41.1                  1.09(0.84-1.42)       0.506       197    55.3                  **1.94(1.45-2.60)**   **0.000**   
  **rs2029167**                                                                                                                                                                                                 
                    AA                                   71         37.2   92     29.7   1.00(ref)                                   42          23.6   1.00(ref)                                               
                    AG                                   83         43.5   103    33.2   0.96(0.63-1.46)       0.841                 51          28.7   1.04(0.62-1.74)       0.885                             
                    GG                                   37         19.4   115    37.1   **2.40(1.48-3.89)**   **0.000**             85          47.8   **3.88(2.26-6.88)**   **0.000**                         
                    AG+GG                                120        62.8   218    70.3   1.40(0.96-2.05)       0.083                 136         76.4   **1.92(1.22-3.02)**   **0.005**                         
                    Allelic frequency                                                                                                                                                                           
                                                         Allele A   225    58.9   287    46.3                  1.00(ref)                         135    37.9                  1.00(ref)                         
                                                         Allele G   157    41.1   333    53.7                  **1.66(1.29-2.15)**   **0.000**   221    62.1                  **2.35(1.75-3.15)**   **0.000**   

Bold values show statistical data with significant difference. \*All *P*-values are adjusted for age, number of sexual partners, age at first intercourse, parities (including full-term pregnancy and abortion at or after 28 weeks) and age at first full-term pregnancy.

###### 

Association between SMUG1 rs3087404 polymorphisms and the risk for CIN III and cervical carcinoma stratified by the sexual, reproductive history

  High risk exposure                 Controls   χ2    *P*    CIN III   χ2     *P*   Carcinoma   χ2      *P*                                                                                                                       
  ---------------------------------- ---------- ----- ------ --------- ------ ----- ----------- ------- ------- ----- ------ ----- ------ ---- ------ ------------ ----------- ---- ------ ----- ------ ----- ------ ------------ -----------
  **Age**                                                                                                                                                                                                                         
                                     ≤ 40       212   35.2   323       53.7   67    11.1        0.036   8.490   93    36.0   120   46.5   45   17.4   0.837        0.360       44   27.5   61    38.1   55    34.4   0.000        0.991
                                     \>40       202   33.8   336       56.2   60    10.0                        48    33.8   62    43.7   32   22.5                            69   28.8   86    35.8   85    35.4                
  **Number of sexual partners**                                                                                                                                                                                                   
                                     ≤ 1        321   33.3   538       55.9   104   10.8        2.590   0.108   120   38.0   151   47.8   45   14.2   **15.610**   **0.000**   93   30.1   126   40.8   90    29.1   **13.468**   **0.000**
                                     \>1        93    39.2   121       51.1   23    9.7                         21    25.0   31    36.9   32   38.1                            20   22.0   21    23.1   50    54.9                
  **Age at the first intercourse**                                                                                                                                                                                                
                                     ≤20        122   34.0   187       52.1   50    13.9        1.364   0.243   32    24.6   57    43.8   41   31.5   **18.453**   **0.000**   26   20.8   36    28.8   63    50.4   **15.528**   **0.000**
                                     \>20       292   34.7   472       56.1   77    9.2                         109   40.4   125   46.3   36   13.3                            87   31.6   111   40.4   77    28.0                
  **Number of parities**                                                                                                                                                                                                          
                                     ≤ 3        184   33.6   299       54.6   65    11.9        1.055   0.304   51    32.3   74    46.8   33   20.9   1.094        0.296       34   26.0   52    39.7   45    34.4   0.069        0.792
                                     \>3        230   35.3   360       55.2   62    9.5                         90    37.2   108   44.6   44   18.2                            79   29.4   95    35.3   95    35.3                
  **Age at the first parity**                                                                                                                                                                                                     
                                     ≤22        84    35.7   131       55.7   20    8.5         0.675   0.411   31    34.1   43    47.3   17   18.7   0.014        0.905       22   24.7   36    40.4   31    34.8   0.183        0.669
                                     \>22       330   34.2   528       54.7   107   11.1                        110   35.6   139   45.0   60   19.4                            91   29.3   111   35.7   109   35.0                
  **HR-HPV infection status**                                                                                                                                                                                                     
                                     Positive   65    34.0   103       53.9   23    12.0        0.595   0.440   111   35.8   143   46.1   56   18.1   0.176        0.675       49   27.5   61    34.3   68    38.2   0.017        0.895
                                     Negative   151   36.1   227       54.3   40    9.6                         16    34.0   21    44.7   10   21.3                            6    26.1   9     39.1   8     34.8                

Bold values show statistical data with significant difference. Stratified analysis were applied by the Kruskal-Wallis H. A *p* value less than 0.05 was considered significant.

###### 

Association between SMUG1 rs2029167 polymorphisms and the risk for CIN and cervical carcinoma stratified by the sexual, reproductive history

  High risk exposure                 Controls   χ2    *P*    CIN III   χ2     *P*   Carcinoma   χ2      *P*                                                                                                                       
  ---------------------------------- ---------- ----- ------ --------- ------ ----- ----------- ------- ------- ----- ------ ----- ------ ----- ------ ------------ ----------- ---- ------ ---- ------ ----- ------ ------------ -----------
  **Age**                                                                                                                                                                                                                         
                                     ≤ 40       234   38.9   278       46.2   90    15.0        2.702   0.100   75    29.1   88    34.1   95    36.8   0.325        0.569       38   23.8   44   27.5   78    48.8   0.513        0.474
                                     \>40       221   37.0   254       42.5   123   20.6                        46    32.4   46    32.4   50    35.2                            59   24.6   75   31.3   106   44.2                
  **Number of sexual partners**                                                                                                                                                                                                   
                                     ≤ 1        362   37.6   431       44.8   170   17.7        0.074   0.786   103   32.6   112   35.4   101   32.0   **10.214**   **0.001**   83   26.9   99   32.0   127   41.1   **12.366**   **0.000**
                                     \>1        93    39.2   101       42.6   43    18.1                        18    21.4   22    26.2   44    52.4                            14   15.4   20   22.0   57    62.6                
  **Age at the first intercourse**                                                                                                                                                                                                
                                     ≤20        132   36.8   164       45.7   63    17.5        0.121   0.728   38    29.2   42    32.3   50    38.5   0.312        0.576       29   23.2   36   28.8   60    48.0   0.274        0.601
                                     \>20       323   38.4   368       43.8   150   17.8                        83    30.7   92    34.1   95    35.2                            68   24.7   83   30.2   124   45.1                
  **Number of parities**                                                                                                                                                                                                          
                                     ≤ 3        202   36.9   238       43.4   108   19.7        1.539   0.215   46    29.1   51    32.3   61    38.6   0.494        0.482       31   23.7   36   27.5   64    48.9   0.416        0.519
                                     \>3        253   38.8   294       45.1   105   16.1                        75    31.0   83    34.3   84    34.7                            66   24.5   83   30.9   120   44.6                
  **Age at the first parity**                                                                                                                                                                                                     
                                     ≤22        88    37.4   101       43.0   46    19.6        0.237   0.626   25    27.5   29    31.9   37    40.7   0.933        0.334       19   21.3   23   25.8   47    52.8   1.797        0.180
                                     \>22       367   38.0   431       44.7   167   17.3                        96    31.1   105   34.0   108   35.0                            78   25.1   96   30.9   137   44.1                
  **HR-HPV infection status**                                                                                                                                                                                                     
                                     Positive   71    37.2   83        43.5   37    19.4        0.028   0.867   92    29.7   103   33.2   115   37.1   0.330        0.566       42   23.6   51   28.7   85    47.8   0.135        0.713
                                     Negative   149   35.6   191       45.7   78    18.7                        16    34.0   15    31.9   16    34.0                            5    21.7   6    26.1   12    52.2                

Bold values show statistical data with significant difference. Stratified analysis were applied by the Kruskal-Wallis H. A *p* value less than 0.05 was considered significant.

###### 

Association between SMUG1 rs3087404 and rs2029167 polymorphisms and the risk for cervical carcinoma stratified by clinical pathological characteristics

  Clinical pathological characteristics   SMUG1 rs3087404   χ2    *P*    SMUG1 rs2029167                χ2     P                                                                         
  --------------------------------------- ----------------- ----- ------ ----------------- ------ ----- ------ ----------- ----------- ---- ------ ----- ------ ----- ------ ----------- -----------
  **Age**                                                                                                                                                                                
                                          ≤ 40              42    26.3   66                41.3   52    32.5   0.022       0.882       36   22.5   52    32.5   72    45.0   0.003       0.955
                                          \>40              71    29.6   81                33.8   88    36.7                           61   25.4   67    27.9   112   46.7               
  **Tumor family history**                                                                                                                                                               
                                          Negative          108   29.4   139               37.9   120   32.7   **8.792**   **0.003**   87   23.7   113   30.8   167   45.5   0.01        0.919
                                          positive          5     15.2   8                 24.2   20    60.6                           10   30.3   6     18.2   17    51.5               
  **FIGO stage**                                                                                                                                                                         
                                          I                 96    28.4   123               36.4   119   35.2   0.002       0.966       84   24.9   103   30.5   151   44.7   1.337       0.248
                                          II                17    27.4   24                38.7   21    33.9                           13   21.0   16    25.8   33    53.2               
  **Tumor size**                                                                                                                                                                         
                                          \<4cm             96    28.8   117               35.1   120   36.0   0.091       0.763       81   24.3   95    28.5   157   47.1   0.474       0.491
                                          ≥4cm              17    25.4   30                44.8   20    29.9                           16   23.9   24    35.8   27    40.3               
  **Differentiation grade**                                                                                                                                                              
                                          Grade I-II        104   30.1   131               37.9   111   32.1   **9.265**   **0.002**   89   25.7   108   31.2   149   43.1   **8.112**   **0.004**
                                          Grade III         9     16.7   16                29.6   29    53.7                           8    14.8   11    20.4   35    64.8               
  **Lymph node metastasis**                                                                                                                                                              
                                          Negative          101   28.1   133               37.0   125   34.8   0.003       0.953       85   23.7   107   29.8   167   46.5   0.599       0.439
                                          positive          12    29.3   14                34.1   15    36.6                           12   29.3   12    29.3   17    41.5               
  **Vascular involvement**                                                                                                                                                               
                                          Negative          96    28.1   127               37.1   119   34.8   0.001       0.979       82   24.0   104   30.4   156   45.6   0.017       0.896
                                          positive          17    29.3   20                34.5   21    36.2                           15   25.9   15    25.9   28    48.3               
  **Stromal invasion**                                                                                                                                                                   
                                          \<2/3             84    29.8   106               37.6   92    32.6   2.363       0.124       74   26.2   84    29.8   124   44.0   2.263       0.132
                                          ≥2/3              29    24.6   41                34.7   48    40.7                           23   19.5   35    29.7   60    50.8               
  **Vaginal wall extension**                                                                                                                                                             
                                          Negative          92    29.0   121               38.2   104   32.8   2.224       0.136       76   24.0   92    29.0   149   47.0   0.438       0.508
                                          positive          21    25.3   26                31.3   36    43.4                           21   25.3   27    32.5   35    42.2               
  **Parametrail extension**                                                                                                                                                              
                                          Negative          104   28.8   135               37.4   122   33.8   1.888       0.169       89   24.7   107   29.6   165   45.7   0.249       0.618
                                          positive          9     23.1   12                30.8   18    46.2                           8    20.5   12    30.8   19    48.7               
  **Endometrial extension**                                                                                                                                                              
                                          Negative          106   28.7   139               37.7   124   33.6   2.767       0.096       91   24.7   111   30.1   167   45.3   1.017       0.313
                                          positive          7     22.6   8                 25.8   16    51.6                           6    19.4   8     25.8   17    54.8               

Bold values show statistical data with significant difference. Stratified analysis were applied by the Kruskal-Wallis H. A P value less than 0.05 was considered significant.

###### 

Genotypes and the risk of all CIN III and cervical carcinoma subjects

  SMUG1 Genotypes^a^   All patients and controls                                                                                               
  -------------------- --------------------------- ------ -- ---- ------ --------------------- ----------- ----- ------ ---------------------- -----------
  AA-AA                158                         13.2      39   9.8    1.00(ref)                         19    4.8    1.00(ref)              
  AA-AG                172                         14.3      37   9.3    0.87(0.53-1.44)       0.589       22    5.5    1.06(0.56-2.04)        0.853
  AA-GG                84                          7.0       65   16.3   **3.14(1.95-5.05)**   **0.000**   72    18.0   **7.13(4.03-12.61)**   **0.000**
  AG-AA                239                         19.9      50   12.5   0.85(0.53-1.35)       0.485       18    4.5    0.63(0.32-1.23)        0.174
  AG-AG                291                         24.3      53   13.3   0.74(0.47-1.17)       0.192       17    4.3    **0.49(0.25-0.96)**    **0.038**
  AG-GG                129                         10.8      79   19.8   **2.45(1.58-3.89)**   **0.000**   112   28.0   **7.22(4.21-12.38)**   **0.000**
  GG-AA                58                          4.8       32   8.0    **2.24(1.28-3.90)**   **0.005**   60    15.0   **8.60(4.73-15.63)**   **0.000**
  GG-AG                69                          5.8       44   11.0   **2.58(1.54-4.32)**   **0.027**   80    20.0   **9.64(5.43-17.13)**   **0.000**
  GG-GG                0                           0.0       1    0.3    **\_**                **\_**      0     0.0    **\_**                 **\_**

Bold values show statistical data with significant difference. ^a^genotypes are composed of two polymorphic sites: rs3087404(A/G), rs2029167(A/G). ^b^All P-values are adjusted for age, number of sexual partners, age at first intercourse, parities (including full-term pregnancy and abortion at or after 28 weeks) and age at first full-term pregnancy.

[^1]: Competing Interests: The authors have declared that no competing interest exists.
